Ready To Get Started?
Contact us to discuss licensing therapeutic assets or initiating a discovery partnership.
Or call (215) 966-6061
INFLUENZA REPORTER VIRUSES
Accelerating the discovery of vaccines and antiviral therapies using influenza A and B pseudoviruses
Influenza Pseudotyped Reporter Virus Particles
.png)
Applications
✔Antibody neutralization
✔Serum screening
✔High-throughput assays
Advantages
✔BSL-2 use
✔Stable HA sequence
✔Quantitative readout
Influenza RVP Product Offerings
For your pandemic and seasonal influenza research, we offer a variety of Influenza A and Influenza B strains. We currently offer strains from the following subtypes and lineages:
Virus | Subtype or lineage |
|---|---|
Influenza A | H1N1 |
Influenza A | H3N2 |
Influenza A | H5N1 |
Influenza B | Yamagata |
Influenza B | Victoria |
Need something you don’t see? We update our catalog regularly, and we can create custom RVPs to meet your needs.
Integral Molecular’s Influenza Reporter Virus Particles (RVPs) are replication-incompetent pseudotyped virus particles that enable safe (BSL-2), easy, and high-throughput viral infectivity and neutralization assays using standard detection instrumentation. The RVPs display hemagglutinin (HA) and neuraminidase (NA) proteins on a heterologous virus core and carry a modified genome that expresses a convenient optical reporter gene (GFP or luciferase).
Conventional hemagglutination and microneutralization assays require handling of live and sometimes highly pathogenic BSL-3 viruses that are subject to drift upon propagation. In contrast, Influenza RVPs are a phenotypically stable, safe, and ready-to-use reagent.
RVP Readouts: agglutination and infection
.png)
A) Influenza RVPs containing HA and NA proteins agglutinated red blood cells upon incubation for 1 hour. B) Infection of HEK-293T cells with Influenza RVPs was inhibited by a neutralizing monoclonal antibody (Sino #68031-H011). A non-neutralizing control antibody did not inhibit infection.
Influenza Expertise
When you use Influenza Reporter Virus Particles, you gain access to our 20+ years of virology experience.
Integral Molecular is the industry leader in providing RVPs for applications including antibody R&D and serum screening for vaccine clinical trials. We also support basic virology research through collaborations and through our own peer-reviewed publications.
- Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors Sulli et al. 2013 Journal of Virology 87(19), 10679
